Related Experiment Video
Updated: May 30, 2026

Determining the Likelihood of Variant Pathogenicity Using Amino Acid-level Signal-to-Noise Analysis of Genetic Variation
Published on: January 16, 2019
A Bayesian Approach for Investigating the Risk of QT Prolongation
1Department of Statistics, NC State University, Raleigh, NC 27695-8203, USA, spanand@ncsu.edu.
Abstract:
The standard approach to investigating a drug for its potential for QT prolongation is to construct a 90% two-sided (or a 95% one-sided) confidence interval (CI), for the difference in baseline corrected mean QTc (heart-rate corrected version of QT) between drug and placebo at each time-point, and to conclude non-inferiority if the upper limit for each CI is less than a pre-specified constant. An alternative approach is to base the non-inferiority inference on the largest difference in population mean QTc (baseline corrected) between drug and placebo. In this paper, we propose a Bayesian approach to resolving this problem using a Monte Carlo simulation method. We use simulated data to assess the performance of the proposed approach, discuss its advantages over the standard approach, and illustrate the method by applying it to a real data set obtained from a thorough QT study conducted at GlaxoSmithKline (GSK).
Related Concept Videos
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast, controlled...
Model-Independent Approaches for Pharmacokinetic Data: Noncompartmental Analysis
One important characteristic of noncompartmental analyses is that drug exposure increases proportionally with increasing doses. This relationship...
Antiarrhythmic Drugs: Class III Agents as Potassium Channel Blockers
Probability Laws
Relative Risk
Detection of Gross Error: The Q Test
